A phase I trial of mRNA-1851
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs MRNA 1851 (Primary)
- Indications Infections
- Focus Adverse reactions; First in man
- 14 Sep 2017 According to a Moderna Therapeutics media release, complete findings are expected in 2018.
- 14 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to a Moderna Therapeutics media release.
- 27 Apr 2017 According to a Moderna Therapeutics media release, 156 healthy volunteers have been dosed in this study till date.